Skip to main content
Premium Trial:

Request an Annual Quote

Tokai, JHU Ink CDx Deal for Castration-Resistant Prostate Cancer Rx Development

NEW YORK (GenomeWeb) – Tokai Pharmaceuticals said today it is working with Johns Hopkins University to develop a companion diagnostic for its investigational, castration-resistant prostate cancer (CRPC) drug galeterone.

Under its agreement, Cambridge, Mass.-based Tokai has garnered an exclusive, worldwide license from JHU for "patent applications and know-how" covering a test used to assess the AR-V7 status of prostate cancer patients.

According to Tokai CEO Jodie Morrison, the company will use the companion test in a 148-patient, Phase III ARMOR3-SV trial, slated to start in the first half of 2015. Tokai is developing galeterone for metastatic CRPC patients who express a truncated version of the androgen receptor, called AR-V7. Galeterone is designed to interrogate androgen receptor signaling, which drives prostate cancer.

Patients with truncated androgen receptors are missing the C-terminal end involved in ligand binding, and AR-V7 is the most frequently occurring splice variant that causes this terminal loss. A prospective JHU study, as well as retrospective analyses by MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, suggests that patients with C-terminal loss and AR-V7 are poor responders to existing metastatic CRPC drugs such as Janssen Biotech's Zytiga (abiraterone acetate) and Astellas' Xtandi (enzalutamide).

Preclinical data generated by Tokai on galeterone, as well as a Phase II trial involving the drug, suggests that it may benefit CRPC patients with AR-V7 and C-terminal loss.

Tokai said it has also finalized an agreement with Qiagen for the development of a non-invasive companion diagnostic for galeterone "utilizing an array of novel technologies."

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.